At the 2023 Association for Research in Vision and Ophthalmology Annual Meeting, Samsung Bioepis shared comparable safety, efficacy, and immunogenicity data through 1 year between its aflibercept biosimilar (SB15) and the originator (Eylea).
Samsung Bioepis shared positive 1-year results from a phase 3 trial confirming the biosimilarity between the company’s aflibercept biosimilar and the originator (Eylea) at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting.
The conference was held April 23-27, 2023, in New Orleans, Louisiana.
Aflibercept is used to treat neovascular age-related macular degeneration (nAMD), a retinal disease that is one of the commonest causes of blindness throughout the world, affecting more than 200 million people globally.
Researchers presented 56 weeks of results from the study. The publication comes after 32-week interim results from the same study were presented at last year’s American Academy of Ophthalmology Annual Meeting in September 2022.
Of a total of 449 patients with nAMD, 438 were randomized to receive either the originator or the biosimilar. At week 32, patients receiving the originator were randomized again to either continue their regimen or switch from to the biosimilar. The biosimilar-only group had 219 patients, the originator-to-biosimilar group had 111, and the originator-only group had 108. Overall, 425 patients were followed through week 56.
The primary efficacy end points were change from baseline in best corrected visual acuity (BCVA), change from baseline in central subfield thickness (CST), and proportion of patients with intra/sub-retinal fluid. Up to week 56, improvements in BCAVA were comparable between all treatment arms. In the group that switched from the originator to the biosimilar, the least square mean change from baseline CST was “well maintained and comparable to the continuing group.”
Additionally, the safety, immunogenicity, and pharmacokinetic profiles of SB15 were clinically similar to the reference product, and no treatment-induced or treatment-boosted anti-drug antibodies developed in the switching group after week 32.
Samsung Bioepis also shared new data on the similarity between SB15 and Eylea in terms of structural and physiochemical properties and biological function at the meeting, showing that the biosimilar had high similarity to the reference product with respect to structural, physiochemical, and biological properties.
“The presentations showcase our ongoing commitment in ophthalmology to bring more access to treatments for patients suffering from retinal vascular diseases…. Biosimilars are relatively new in ophthalmology compared to other therapeutic areas, and we will continue to advance with our scientific research, publication and educational activities to bring more awareness of biosimilars among ophthalmologists,” said Jin-Ah Jung, medical affairs group leader at Samsung Bioepis, in a statement.
In November 2019, Samsung Bioepis entered into a commercialization agreement for SB15 and SB11, a ranibizumab biosimilar also used to treat nAMD as well as other ophthalmic conditions. SB11, also known as Byooviz, references Lucentis and is currently available on the US, EU, and Canadian markets.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
2 Commerce Drive
Cranbury, NJ 08512